Supplemental Table 2: Changes among tesamorelin-treated subjects with baseline ALT or AST > 30 U/L by VAT responder status at week 26

A) Changes in ALT, AST, and VAT

	Baseline			**∆ (Week 26 – Week 0)**		
	Responder (n = 177)	**Nonresponder** (n = 80)	***P*-value**	**Responder** (n = 176)	**Nonresponder** (n = 79)	***P*-value**
ALT (U/L)	50.0 ± 20.3	52.9 ± 23.2	0.31	-8.9 ± 22.6	1.4 ± 34.7	**0.004**[1]
AST (U/L)	37.4 ± 12.9	38.8 ± 15.0	0.46	-3.8 ± 12.9	0.4 ± 22.4	**0.04**[1]
VAT (cm^2)	190 ± 83	202 ± 77	0.27	-51 ± 34	16 ± 27	N/A

B) Frequency of resolution of abnormal liver enzymes (ALT or AST ≤ 30 U/L at week 26)

	Responder (n = 176)	**Nonresponder** (n = 79)	***P*-value**	**Odds Ratio (95% CI)**
ALT (U/L)	35%	18%	**0.007**	**2.5 (1.2, 5.3)**[2]
AST (U/L)	52%	41%	0.10	1.5 (0.8, 2.8)[2]

Mean ± SD

ALT, alanine aminotransferase; AST, aspartate aminotransferase; VAT, visceral adipose tissue.

[1]*P*-value for responder status is based on the following model: ∆ ALT or AST = baseline ALT or AST + responder status + clinical trial + viral hepatitis status

[2]Odds Ratio for responder vs. nonresponder is based on the following model: ALT or AST ≤ 30 U/L = baseline ALT or AST + responder status + clinical trial + viral hepatitis status